Opus Genetics reports positive OPGx-BEST1 Phase 1/2 data
Opus Genetics reported positive safety and proof-of-concept results from low-dose Cohort 1 of OPGx-BEST1, with functional and structural gains in treated patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Opus Genetics reports positive OPGx-BEST1 Phase 1/2 cohort 1 data
OPGx-BEST1 showed a favorable safety and tolerability profile in cohort 1, with no serious adverse events or dose-limiting toxicities observed. All five participants showed clinically meaningful visual function improvement.